Hims & Hers Health, Inc. filings document the regulatory record for a public consumer telehealth company offering access to health-and-wellness treatments through its digital platform. Its disclosures include operating and financial results, shareholder letters, material-event reports and clinical or regulatory updates related to products and services available through the platform, including weight loss care.
Proxy and 8-K filings cover board elections, executive compensation, shareholder voting matters, governance practices and capital-structure disclosures. The filing record also documents Class A common stock matters, share repurchase authorizations, material agreements, Regulation FD disclosures and other events affecting the company’s public-company reporting obligations.
Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton sold 3,461 shares of Class A Common Stock on October 14, 2026, at $29.06 per share. The sale was made under a Rule 10b5-1 trading plan adopted on May 21, 2026. After the sale, Boughton directly held 297,348 shares.
Jonathan M. Franklin is identified as Chief Accounting Officer of Hims & Hers Health, Inc. (HIMS) in an initial ownership report; no transactions are reported.
Hims & Hers Health, Inc. (HIMS) is the issuer named in a Form 144 notice concerning officer Soleil Boughton’s proposed sale of 3,461 Class A shares, with an aggregate market value of $100,576.66. The sale date shown is October 14, 2026. The shares are identified as compensation from restricted stock vesting on August 15, 2026, and Fidelity Brokerage Services LLC is listed as broker. The notice also lists four earlier sales by Soleil Boughton, dated August 19 through September 30, 2026.
Hims & Hers Health, Inc. appointed Jonathan M. Franklin as principal accounting officer, effective October 9, 2026, concurrently with Irene Becklund’s previously disclosed resignation from that role. Franklin began employment as chief accounting officer on October 5, 2026. Becklund’s advisory agreement takes effect October 10, 2026, and provides for her support through July 10, 2027.
Franklin’s compensation includes a $425,000 annual base salary, a $150,000 signing bonus payable in installments subject to nine months of continued service, and restricted stock units with a $3,000,000 grant value. He is also eligible for an annual discretionary bonus targeted at 50% of his base salary. The restricted stock units vest 25% on the first quarterly vesting date on or after the one-year anniversary of the vesting commencement date; the remaining 75% vest in approximately equal quarterly installments over the following three years.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe sold 2,000 shares of Class A Common Stock at $29.70 per share on October 1, 2026. The sale was made under a Rule 10b5-1 trading plan adopted on May 20, 2026. His reported direct holdings after the sale were 234,527 shares.
Hims & Hers Health, Inc. (HIMS) Chief Legal Officer Soleil Boughton sold 3,461 shares of Class A Common Stock at $29.17 per share on September 30, 2026, under a Rule 10b5-1 trading plan adopted on May 21, 2026. The transaction is described as a sale in the open market or a private transaction. Following the sale, Boughton directly held 300,809 shares.
Hims & Hers Health, Inc. officer Oluyemi Okupe reported a proposed sale of 2,000 Class A shares, with an aggregate market value of $59,400 and an approximate sale date of October 1, 2026. The notice lists prior sales during the preceding three months: 12,313 shares on September 17, 2026, for $354,860.66, and 29,277 shares on September 22, 2026, for $876,846.15.
Hims & Hers Health, Inc. (HIMS) is named in a Form 144 notice for a proposed sale by Officer Soleil Boughton of 3,461 Class A shares, with an aggregate market value of $100,957.37 and an approximate sale date of September 30, 2026. The notice also lists three sales during the preceding three months: 25,111 shares on August 19, 3,458 shares on September 2, and 6,236 shares on September 16, 2026.
Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe exercised options for 14,000 Class A common shares at $5.01 per share and sold 29,277 shares at $29.95 per share on September 22, 2026. The option award was fully vested, and the exercise and sale were made under a Rule 10b5-1 trading plan adopted on May 20, 2026. After the exercise, he reported 66,872 options; 7,853 Class A common shares were held indirectly by the Oluyemi Okupe Separate Property Trust.
Hims & Hers Health, Inc. (HIMS) is the issuer referenced in a notice under Rule 144 for a proposed sale of 29,277 shares of Class A common stock for the account of officer Okupe Oluyemi. The filing lists an aggregate market value of $876,846.15 for these shares and notes 224,935,790 Class A shares outstanding as of September 22, 2026.
The shares to be sold were acquired through a stock option exercise of 14,000 shares and multiple restricted stock vestings between March 15, 2025 and August 15, 2026. The document also reports a prior sale of 12,313 Class A shares for $354,860.66 on June 17, 2026 under Rule 144 aggregation requirements.